| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 13,974.85 | 12,297.92 | 10,530.7 | 9,325.94 |
Net Worth | 13,998.76 | 12,321.83 | 10,554.61 | 9,349.85 |
Minority Interest | ||||
Debt | 611.44 | 438.71 | 1,005.21 | 1,181.69 |
Deferred Tax Liability Net | 155.72 | 231.21 | 253.55 | 207.82 |
Total Liabilities | 14,765.92 | 12,991.75 | 11,813.37 | 10,739.36 |
Fixed Assets | 1,672.29 | 1,667.84 | 1,873.02 | 2,053.84 |
Intangible Assets | ||||
Investments | 5,551.93 | 4,406.78 | 2,828.98 | 3,005.55 |
Deferred Tax Asset Net | 1,677.81 | 1,660.35 | 1,540.21 | 1,292.74 |
Networking Capital | 4,574.42 | 4,200.67 | 4,505.31 | 2,223.36 |
Inventories | 1,631.76 | 1,522.9 | 1,849.56 | 1,724.66 |
Inventory Days | ||||
Sundry Debtors | 1,567.24 | 1,559.84 | 1,753.64 | 1,768.34 |
Debtor Days | ||||
Other Current Assets | 4,026.35 | 3,952.99 | 3,380.09 | 930.04 |
Sundry Creditors | -1,476.13 | -1,463.78 | -1,570.94 | -1,076.34 |
Creditor Days | ||||
Other Current Liabilities | -1,174.8 | -1,371.28 | -907.04 | -1,123.34 |
Cash | 1,289.47 | 1,056.11 | 1,065.85 | 2,163.87 |
Total Assets | 14,765.92 | 12,991.75 | 11,813.37 | 10,739.36 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
